Oliclinomel N7-1000e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The mixture supplies a balanced profile of essential and non‑essential amino acids directly into the bloodstream. These amino acids serve as building blocks for protein synthesis, support nitrogen balance, and aid hepatic metabolism, thereby helping maintain tissue integrity and promote healing when oral intake is insufficient.

The dosage of Oliclinomel N7-1000e is individualized by the prescribing clinician based on the patient’s weight, metabolic needs, and clinical condition. The healthcare professional determines the infusion rate and total daily amount to achieve the desired nitrogen and protein targets.

Safety data for Oliclinomel N7-1000e in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Oliclinomel N7-1000e offers a comprehensive blend of ten essential amino acids in a single sterile solution, comparable to other amino acid formulations used for total parenteral nutrition. Differences may lie in the specific amino‑acid ratios, osmolarity, and compatibility with other TPN components, which clinicians consider when selecting a product for individual patient needs.

The solution must be stored refrigerated at 2–8 °C, protected from light, and must not be frozen or shaken. Before use, inspect the container for particulate matter or discoloration, and allow the product to reach room temperature if required for infusion, following aseptic technique.

Oliclinomel N7-1000e is administered intravenously, typically via a central venous catheter or a peripheral line, as part of a total parenteral nutrition regimen. The infusion rate is set by the healthcare provider and delivered using an infusion pump to ensure accurate dosing and to monitor for any adverse reactions.

The most serious risks include anaphylactic or severe hypersensitivity reactions, metabolic acidosis, hyperammonemia (especially in patients with liver dysfunction), and significant electrolyte disturbances. Prompt recognition of symptoms such as rash, difficulty breathing, rapid heart rate, or sudden changes in laboratory values is essential for immediate intervention.

Patients with known hypersensitivity to any component of the solution, severe hepatic impairment, uncontrolled electrolyte imbalances, or those for whom intravenous nutrition is contraindicated should not receive Oliclinomel N7-1000e. Clinical judgment is required to assess suitability on an individual basis.